TickerGraveyard
TickerGraveyard

OPT

Delisted
Opthea Ltd

OPT — Post-Mortem

Opthea Ltd, a biotechnology firm focused on ophthalmic therapies, experienced a significant decline in its market presence leading to its delisting from the Nasdaq on November 10, 2025. The peak of its stock performance occurred much earlier, but by the time of its delisting, the company had failed to adhere to the Nasdaq Listing Rule 5605(c)(2) concerning audit committee composition. This failure was indicative of broader governance issues and ultimately resulted in the company’s decision to file Form 25, signaling its removal from the exchange. As a testament to the importance of compliance in maintaining a public listing, this delisting serves as a case study on the implications of governance deficiencies in the biotechnology sector.

Opthea Ltd was delisted from Nasdaq on November 10, 2025, due to non-compliance with audit committee requirements.

Could I Have Seen This Coming?

No structured pre-delisting signals found in our records. Absence of signals does not imply absence of risk.

Post-Mortem Analysis

Five-section narrative grounded in primary filings and contemporaneous reporting.

Origin

Opthea Ltd was founded to address unmet medical needs in retinal diseases but faced various operational and governance challenges over time.

Peak

The company's stock experienced its highest value prior to its operational decline and governance issues, leading to scrutiny from Nasdaq.

Turning Point

The critical turning point for Opthea Ltd was its inability to meet Nasdaq's audit committee requirements, triggering the delisting process.

End

Opthea Ltd's delisting from Nasdaq was formalized on November 10, 2025.

Impact

The delisting has significant implications for existing shareholders, who now face limited options for liquidating their investments.

Lessons for Today's Investors

Transferable patterns identified from this case, written as research-report observations.

  1. 1

    Companies must maintain compliance with exchange listing standards to avoid delisting.

  2. 2

    The absence of an audit committee can lead to regulatory repercussions, reflecting on governance practices.

  3. 3

    Clear communication with stakeholders during times of compliance issues is crucial to maintain trust.

Frequently Asked Questions

Why was Opthea Ltd delisted from the Nasdaq?
Opthea Ltd was delisted due to its failure to meet the audit committee composition requirements mandated by Nasdaq Listing Rule 5605(c)(2).
What is the significance of Form 25?
Form 25 is filed with the SEC to notify the removal of a security from listing on an exchange, signaling the company's voluntary decision to withdraw its registration.
Who signed the Form 25 for Opthea Ltd?
The Form 25 was signed by Jeremy Levin, the Chief Executive Officer of Opthea Ltd.
What is the effective date of the delisting?
The delisting was officially notified on November 10, 2025.

Source Filings

Every fact on this page is anchored to a primary SEC filing or regulatory record. Open any source to verify against the original document.

Narrative sections on this page are AI-assisted summaries of the filings linked above. All content is reviewed against primary sources; if you find an error, the canonical record is always the linked filing.

Categories:

Industries:

Tags:

Related tickers:

Share: